Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC)-2-year event-free survival and safety data for Cohort H Meeting Abstract
| Authors: | O'Donnell, P. H.; Hoimes, C. J.; Rosenberg, J. E.; Petrylak, D. P.; Mar, N.; Barata, P. C.; Srinivas, S.; Gourdin, T. S.; Henry, E.; Bilen, M. A.; George, S.; Rao, S.; Assikis, V. J.; Burgess, E. F.; Lewis, B. E.; Bowman, I. A.; Brancato, S. J.; Mildiner-Earley, S.; Zhu, Y.; Flaig, T. W. |
| Abstract Title: | Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC)-2-year event-free survival and safety data for Cohort H |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557401207 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.4564 |
| Notes: | Meeting Abstract: 4564 -- Source: Wos |
